

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or an offer to acquire, purchase or subscribe for the securities of the Company referred to in this announcement.



GENOR BIOPHARMA HOLDINGS LIMITED

嘉和生物藥業（開曼）控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6998)

ANNOUNCEMENT

- (1) VERY SUBSTANTIAL ACQUISITION AND CONNECTED TRANSACTION – PROPOSED MERGER BETWEEN THE MERGER SUB AND THE TARGET INVOLVING ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE;**
(2) REVERSE TAKEOVER INVOLVING THE NEW LISTING APPLICATION;
(3) APPLICATION FOR WHITEWASH WAIVER;
(4) SPECIAL DEAL IN RELATION TO THE RETENTION PLAN OF THE SHAREHOLDER PERSONNEL;
(5) PROPOSED CHANGE OF COMPANY NAME;
(6) PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY; AND
(7) PROPOSED ADOPTION OF THE ONE-OFF SHARE OPTION PLAN
- MONTHLY UPDATE AND DELAY IN DESPATCH OF CIRCULAR**

Reference is made to the announcements of Genor Biopharma Holdings Limited (the “**Company**”) (i) dated 7 October 2024 (the “**First Announcement**”) in relation to, among other things, the Proposed Merger, the New Listing Application, the Whitewash Waiver, the Retention Plan of the Shareholder Personnel, the Proposed Change of Company Name, the proposed increase in authorised share capital of the Company and the proposed adoption of the One-off Share Option Plan (collectively, the “**Transactions**”), (ii) dated 28 October 2024 and 26 June 2025 in relation to the delay in despatch of the Circular; (iii) dated 26 November 2024 in relation to the appointment of Independent Financial Adviser; (iv) dated 28 November 2024, 27 December 2024, 24 January 2025, 25 February 2025, 25 March 2025, 15 May 2025, 13 June 2025, 25 July 2025, 25 August 2025 and 25 September 2025 in relation to the monthly updates on the Transactions; and (v) dated 15 April 2025 in relation to the filing of the New Listing Application. Unless otherwise specified, capitalised terms used herein shall have the same meanings as those defined in the First Announcement.

As disclosed in the announcement of the Company dated 15 April 2025, the Company submitted the New Listing Application to the Stock Exchange on 15 April 2025 through its joint sponsors. Further, as disclosed in the announcement of the Company dated 26 June 2025, the time for despatch of the Circular has been extended to on or before 31 October 2025. The Company wishes to update the Shareholders that the Company has been working closely with all professional parties to address comments from the regulators on the Circular.

Further, as additional time is required by the Company to address comments from the regulators on the Circular and to update the information contained therein, an application has been made by the Company to the Executive pursuant to Rule 8.2 of the Takeovers Code for, and the Executive has indicated that it is minded to grant, its consent to an extension of time for the despatch of the Circular to the Shareholders to a date falling on or before 30 November 2025.

The Company will also make announcement(s) to update the Shareholders and investors of any material development as soon as possible.

WARNING

Shareholders and potential investors should note that the Merger Closing is subject to the fulfilment or waiver (as the case may be) of the Merger Conditions Precedent. In addition, the Listing Committee of the Stock Exchange may or may not approve the New Listing Application to be made by the Company. In the event that approval of the New Listing Application is not granted, the Merger Agreement will not become unconditional and the Proposed Merger will not proceed.

The Executive may or may not grant the Whitewash Waiver. It is one of the Merger Conditions Precedent that the Whitewash Waiver has been granted. In the event that the Whitewash Waiver is not granted by the Executive or the Whitewash Waiver and the Proposed Merger are not approved by the Independent Shareholders at the EGM, the Merger Agreement will not become unconditional and the Proposed Merger will not proceed.

As the Merger Closing may or may not take place, Shareholders and potential investors are reminded to exercise caution when dealing in the Shares.

By order of the Board
Genor Biopharma Holdings Limited
Mr. Weng Chengyi
Executive Director and Chief Financial Officer

Hong Kong, 27 October 2025

As at the date of this announcement, the Board comprises six (6) Directors, namely Mr. Weng Chengyi (Chief Financial Officer) as an executive Director; Mr. Yu Tieming and Mr. Liu Yi as non-executive Directors; and Ms. Cui Bai, Mr. Fung Edwin and Mr. Chen Wen as independent non-executive Directors.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.